Allogene Therapeutics (ALLO) Profit After Tax (2018 - 2026)

Allogene Therapeutics has reported Profit After Tax for 9 years, with the latest figure at -$43.1 million in Q1 2026.

• Quarterly Profit After Tax rose 27.75% year-over-year to -$43.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$173.6 million (up 31.24% YoY) and the FY2025 annual result came in at -$190.5 million, up 25.78% from the prior year.
• Profit After Tax eased to -$43.1 million in Q1 2026 per ALLO's latest filing, from -$38.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$38.5 million in Q4 2025 and troughed at -$100.0 million in Q1 2023.
• A 5-year average of -$67.6 million and a median of -$66.3 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax slumped 3438.56% in 2022, then surged 37.97% in 2025.
• Over 5 years, Profit After Tax stood at -$97.3 million in 2022, then advanced by 21.04% to -$76.8 million in 2023, then advanced by 21.64% to -$60.2 million in 2024, then surged by 36.11% to -$38.5 million in 2025, then retreated by 11.98% to -$43.1 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$43.1 million, -$38.5 million, and -$41.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.